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Abstract Approximately 50 % of patients with heart fail-
ure have diastolic heart failure (HFPEF) with the major
predisposing risk factors age, inactivity, obesity, insulin
resistance (IR), type-2 diabetes, and hypertension. The
prognosis of HFPEF is comparable to that of systolic
heart failure, but without any specific or effective treat-
ment. This review presents a biomathematically corrected
diagnostic approach for quantification of diastolic dys-
function (DD) via the age dependency of diastolic func-
tion. Pathophysiological mechanisms for DD in the car-
diometabolic syndrome (CMS) are mainly based on
downstream effects of IR including insufficient myocar-
dial energy supply. The second section discusses thera-
peutic strategies for the control and therapy of CMS, IR,
and the associated DD/HFPEF with a focus on dietary
therapy that is independent of weight loss but improves
all manifestations of the CMS and reduces cardiovascular
risk.
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Abbreviations
CAD Coronary artery disease
CMS Cardiometabolic syndrome
DD Diastolic dysfunction
HDL High-density lipoprotein cholesterol
HF Heart failure
IR Insulin resistance
LDL Low-density lipoprotein cholesterol
LV Left ventricle
MUFA Monounsaturated fatty acids
RAAS Renin-angiotensin-aldosterone system
VDLDL Very dense LDL particles
Introduction
The cardiometabolic syndrome (CMS), also known as
insulin resistance (IR) syndrome [1], is a combination
of primarily metabolic disorders with IR as the underly-
ing disorder. Its strong link with cardiovascular disease
makes CMS the leading cause of morbidity and mortality
in the Western world [2, 3].
However, the perilous consequences of CMS are not only
coronary artery disease (CAD) but also non-ischemic myocar-
dial dysfunction and heart failure (HF) [4] associated with
obesity cardiomyopathy, insulin resistance cardiomyopathy,
and diabetes cardiomyopathy [5–7] which suggest that IR is
the underlying disorder [8]. Indeed, IR and HF are strongly
correlated [9–13] with causal associations between IR and
cardiac dysfunction that are observed in the development of
IR by genetic and also by environmental factors [14]. In ad-
dition, HF predisposes to the development of cardiac and/or
systemic IR and type-2-diabetes [15].
The reciprocal relationship between IR and HF is important
because it implies therapeutic potential for HFPEF and its
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predecessor diastolic dysfunction (DD): prevalence and prog-
nosis of HFPEF equal those of systolic HF [4, 16–18] but
therapeutic studies have been unsuccessful [19, 20••, 21••].
This review discusses underlying pathophysiological mecha-
nisms of DD/HF associated with CMS, a potential solution to
diagnostic problems and the resulting options for therapy.
CMS and DD/HFPEF
Background and Prevalence of CMS
CMS has been defined by the World Health Organization and
the National Cholesterol Education Program Adult Treatment
Panel III with central obesity and IR as key risks [22••]. The
diagnosis requires the presence of any three out of these fac-
tors: hyperglycemia (as ultimate result of IR), hypertension,
central obesity, dyslipoproteinemia (high triglyceride and/or
low high-density lipoprotein (HDL) levels). Age contributes
to an increased prevalence of CMS so that an epidemic in-
crease in CMS and its downstream effects on CAD, stroke,
and HF imply an ominous impact worldwide [22••].
Approximately 34 % of the adult US population and about
4 % of the adolescents have CMS that is most frequently
driven by obesity. The prevalence of CMS is estimated at
15–25 % in European adults and ranges in the Middle East
from 20–37 % in the Gulf States to 28–39 % in Turkey or in
urban populations of India [22••].
Prevalence and Clinical Signs of DD/HFPEF
Over the last two decades, HFPEF has become an increas-
ingly important problem. Prevalence of its preceding ab-
normality DD is high, ranging from 11 to 27 % in the
general adult population, but with a mean of 35 % in indi-
viduals with CMS, 12, 35, and 45 % in increasing severity
of obesity and 50–70 % in pre-diabetes and in type-2 dia-
betes [8, 20••, 23]. However, the triggers for the progres-
sive transition into clinical HF remain to be clarified [20••].
The typical clinical symptoms are exertional dyspnea and
decreased exercise capacity, leading to reduced quality of life
especially in the elderly. If diastolic function at rest is normal,
diastolic reserve should be assessed and a 6-min walking test
scheduled. In spite of the known risk factors overweight, IR
and type-2 diabetes, DD is under diagnosed in these individ-
uals who often conceal their reduced physical performance or
have scaled down their activities.
Pathophysiological Mechanisms in CMS Associated Risk
for HF
A fundamental principle is known from the ischemic cascade:
insufficient energy/oxygen supply initially impairs myocardi-
al diastolic function and only subsequently results in systolic
dysfunction [24]. This immediate effect is reversible and with-
out any changes of myocardial structure.
Accordingly, a two-step model appears meaningful for HF
and the preceding DD associated with CMS: Its risk factors
obesity, IR, type-2 diabetes, dyslipoproteinemia, and hyper-
tension metabolically induce insufficient energy supply, inter-
mittently, repetitively, and reversibly [23, 25, 26•]. In a second
step, remodeling mechanisms increase myocardial stiffness
and impair late diastolic function. An early and potentially
treatable cause such as IR may be differentiated from later
remodeling so that therapeutic interventions would not any
more target myocardial stiffness alone but focus on earlier
metabolic factors in favor of potential prevention.
Overweight impacts on more than half the adult population
leading most often to IR. This applies also to cardiology pa-
tients and implies metabolic constraints for myocardial energy
supply in addition to the individual cardiac disease [8, 25, 27].
Recently, IR was confirmed as one of the three top risk factors
for DD in non-diabetic individuals and the top risk factor in
type-2 diabetes [21••].
Insulin Signaling Links to Cardiac Function
Cardiac IR may develop independently of systemic IR. More
often and subsequent to prolonged or excessive overnutrition,
systemic IR relevantly contributes to secondary cardiac IR
with oxidative stress and neurohumoral/sympathetic and/or
cytokine imbalance. Two different pathways of insulin signal-
ing impact on cardiac function [13]:
& The phosphatidylinositol-3 kinase/protein kinase B (Akt)
signaling pathway elicits mainly beneficial metabolic re-
sponses. The downstream mechanisms include the activa-
tion of Akt and atypical protein kinase-C isoforms medi-
ating the following reactions: Glucose transporter type-4
(Glut4) translocation leading to glucose uptake in
myocardial/muscular tissue, nitric oxide mediated coro-
nary dilatation, metabolic substrate flexibility and energy
homeostasis, and balanced calcium handling.
& The mitogen-activated protein kinase (MAPK) signaling
pathway elicits growth factor-like responses that contrib-
ute to growth and remodeling responses such as
myocellular hypertrophy, cardiac fibrosis, impaired
myocardial-endothelial signaling and death of myocardial
and endothelial cells.
The resultant complex and reciprocal metabolic mecha-
nisms involve altered substrate use and decreased myocardial
ATP generation, endothelium induced dysregulation of myo-
cardial perfusion and impaired calcium handling that lead to
DD in its early stage (Fig. 1) before inflammatory and cyto-
kine abnormalities, lipo- and glucotoxicity, oxidative stress
from reactive oxygen species, upregulation of the renin-
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angiotensin-aldosterone (RAAS) and sympathetic nervous
system induce remodeling processes. These imply
myocellular hypertrophy, fibrosis, collagen, and titin modifi-
cations and accumulation of triglycerides and/or advanced
glycemic end products leading to cell damage and further
deterioration of DD and also contractile function. The specific
impact and sequence of these mechanisms for the develop-
ment of HF in man remain to be clarified [13, 14, 19, 20••,
27, 28].
Diagnostic Criteria for the Risk of HF in CMS
HFPEF/DD is a functional diagnosis with many different
comorbidities. The major risk factors are age and CMS
that include obesity, IR, type-2 diabetes, and hyperten-
sion, furthermore CAD, anemia, chronic obstructive pul-
monary disease, sleep apnea, renal disease, and rare con-
genital abnormalities. Given the epidemic of CMS, early
accurate diagnosis of DD is of pivotal importance for the
development of preventive strategies. In contrast to
HFREF and systolic dysfunction, there is no consensus
as to how to quantify DD [8, 20••, 25]. This problem
contributes to the lack of clinically relevant results in
therapeutic studies [16, 20••, 26•].
The European and American guidelines define DD as an
abnormal LV filling pressure that may be estimated non-
invasively by E/E’ >15. For the intermediate range 8–15, ad-
ditional parameters of potential DD involve mainly increased
left atrial volume or LV mass, a diminished mitral inflow ratio
E/A and/or biomarkers [17]. These echocardiographic metrics
were considered partly non-sensitive or inconclusive [21••,
29]. A single criterion for quantification of myocardial diastol-
ic function is not available to assess DD although tissue
Doppler derived E’ has prognostic potential and also corre-
lates with exercise capacity [8, 30••, 31].
A biomathematical approach may solve this diagnostic
problem: age is such a dominant determinant of diastolic myo-
cardial function that it accounts for 88 % predictability of
diastolic function but only 39 % of systolic function [21••].
Accordingly, DD needs to be defined as the deficit between
the E’ and an age-related normal value from healthy individ-
uals E’norm (Fig. 2). Consequently, risk factors for DD are a
function of this deficit E’norm – E’. This approach avoids the
biomathematical error of defining risk factors that also depend
Fig. 1 Molecular mechanisms in cardiac insulin resistance via
overnutrition and impaired insulin signaling leading to repetitive
intermittent lack of energy in the early stage of cardiac dysfunction that
is DD. The progression to remodeling processes including myocellular
hypertrophy, altered titin, collagen and fibrosis metabolism, accumulation
of triglycrides, and/or advanced glycemic end products and also the
activation of the renin-angiotensin and sympathetic nervous system will
lead to further myocardial cell damage and, potentially, to contractile
dysfunction and/or heart failure. Ang II angiotensin II, ROS reactive ox-
ygen species, ER endoplasmatic reticulum, eNOS endothelial nitric oxide
synthase, SERCA sarcoplasmic endoplasmic reticulum Ca2+ - ATPase
2a, SR sarcoplasmatic reticulum (modified from [13])
Curr Heart Fail Rep (2016) 13:219–229 221
heavily on age. Instead, the central importance of metabolic
abnormality, i.e. IR, is revealed [21••].
Non-Pharmacological Therapeutic Strategies for CMS
The epidemic of CMS is mainly caused by environmental
factors such as inactivity and the availability of cheap and
Bfast^ foods rich in energy from starches and fat. The
singlemajor cause of poor health in cardiology patients is poor
diet.
However, doctors receive very little training in healthy nu-
trition in spite of reviews that actually remove the ban from fat
and demonstrate the risks of high carbohydrate intake [32••,
33••, 34].
Dietary approaches
In CMS, dietary approaches aim for these issues: (1) weight
normalization and maintenance long-term, (2) elimination of
postprandial glucose and insulin peaks without weight loss,
and (3) reduction of the risk factors dyslipoproteinemia and
hypertension.
(1) Weight Reduction and Maintenance:
A relevant reduction of weight may abolish IR/
hyperinsulinemia by the reduction of ectopic fat accumulation
and improve all manifestations of the CMS [35]. It is achieved
rather by diet than by exercise only [36]. The fundamental
hypocaloric nutrition renders various diets suitable:
& Low-fat nutrition has been traditionally recommended as
restriction of fat to about 60 g daily and high carbohydrate
ingestion [34, 37•]. Via a daily energy deficit of 500 kcal,
mean weight loss may be 3–4 kg within 6 months follow-
ed commonly by a regain in weight [38, 39]. There is no
evidence for more effective weight loss compared to other
hypocaloric diets [40] but evidence for a long-term in-
crease of overweight and cardiovascular disease [32••,
41, 42].
& Carbohydrate restricted diets show superior weight loss
by about 3 kg within 6 months if compared to low-fat diets
[43, 44] with some subsequent regain, so that weight loss
at 12 months is 1–2 kg greater but not significant [44].
& Carbohydrate modification implies a reduction of glyce-
mic index (GI) and glycemic load (GL) (table) resulting
effectively in weight loss [45••, 46, 47]. An example is the
LOGI (low glycemic and insulinemic) method [48] based
on recommendations for obesity therapy at the Boston
children’s hospital [49] with avoidance of refined starch
and saccharose products and preference for food with low
GI (vegetable, legumes, and whole grain products) mini-
mizing postprandial glucose and insulin peaks [46]. Meta-
analysis demonstrates superior weight loss within
6 months for diets with reduced GI and/or GL including
the Mediterranean diet [46, 47]. Additionally, the cardio-
vascular risk factors dyslipoproteinemia, hypertension
[30••, 37•, 50, 51], and IR are improved [30••, 52].
Only 20 % of subjects maintain weight loss long-term.
Attainment of this goal may be supported by two measures:
& A decrease of energy density to <125 kcal/100 g of con-
sumed food is recommended given population based
values of ≥160 kcal/100 g [34]. This aim requires to con-
sumemore food high in water and fibers (salad, vegetable,
fruit, fish, milk/milk products, and lean meat) and less
high-energy food (fast food rich in fat and sugar, custom-
ary bakery products, sugared lemonades, and fruit juices)
[53]. An advisable low-energy meal may be a salad with
Type-2 DiabetesNon-Diabetic Controls
Fig. 2 Diastolic myocardial function E’ as function of age in non-
diabetic controls (left) and type-2 diabetes (right) with the regression line
(black) and upper and lower tolerance intervals (purple and green) from
healthy controls. Diastolic dysfunction is defined as difference E’ – E’norm
on the regression line >2.86 (shaded triangle) and risk for diastolic dys-
function if the deficit is >50 % of this cut off level (between the dashed
line and the lower tolerance line) (modified from [21••])
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breast of turkey and olive oil dressing in spite of its 40 %
content in fat [48].
& Improved satiety is achieved by increasing water and
fiber content of food and protein intake to a total of
30 % (about 2 g/kg body weight) [47, 54]. In healthy
people, no harm has been shown for such a moderate
increase of protein intake but advantages for maintaining
weight loss [55].
(2) GL Restriction for Normalizing IR Without Weight
Loss:
In the course of CMS, long-term normalization of weight is
often unrealistic. Hence, dietary strategies are preferable that
normalize postprandial insulin and glucose peaks and IR in-
dependent of weight loss in these high risk individuals [56].
Postprandial hyperglycemia subsequent to a carbohydrate
meal is common in individuals with IR. The associated fluc-
tuations of glucose and insulin are known cardiovascular risk
factors [57, 58] depending mainly on two mechanisms:
& Reduced insulin sensitivity, i.e., IR leads to higher post-
prandial glucose peaks in these compared to insulin
sensitive individuals [48, 59]. The more insulin resistant
a person is, the more insulin is required to keep
blood glucose within normal limits rendering the normal-
ization of hyperinsulinemia/IR an important therapeutic
target.
& Postprandial glucose values are directly determined by the
quality, i.e. GI, and quantity, i.e. GL, of the consumed
carbohydrates. Their specific reduction provides a practical
tool to prevent postprandial hyperglycemia and
hyperinsulinemia (Table 1) [57, 60]. In lean healthy indi-
viduals, 37 % of the postprandial glucose levels are deter-
mined by GI, but 90 % by GL that contributes also to a
greater extent to atherogenic dyslipoproteinemia [32••, 61].
GL restriction has several advantages: (a) Preclusion of
hunger attacks between meals by hyperinsulinemia with rela-
tive hypoglycemia, (b) unlimited access to other macronutri-
ents inducing improved satiety and maintenance of weight
loss [55], (c) a reduction of cardiovascular risk and IR inde-
pendent of weight loss [30••, 45••, 51, 52, 56, 62, 63], and (d)
a reduction or abolishment of antidiabetic medication in line
with preventing hypoglycemia [30••, 45••].This return to a
healthier life increases patients’ compliance and minimizes
the potentially ominous side effects of antidiabetics [64]. A
GL restriction is now implemented in the guidelines for type-2
diabetes [65]. Substantial evidence supports its therapeutic use
as safe and immediately effective [32••, 37•, 43, 50, 63, 66,
67].
(3) Reduction of Dyslipoproteinemia and Hypertension:
High triglyceride, VDLDL, LDL, and low HDL cholesterol
levels characterize the atherogenic dyslipoproteinemia in
CMS that may be improved by macronutrient modification
without weight loss [34, 68]. Low-fat/high-carbohydrate nu-
trition effectively reduced LDL but deteriorated triglycerides,
VDLDL, and HDL [69]. However, a partial replacement of
carbohydrate content with an isocaloric amount of fat (prefer-
ably monounsaturated fatty acids (MUFA)) improved all fac-
tors of dyslipoproteinemia, confirmed in meta-analysis for
healthy and diabetic individuals and the Mediterranean diet
[44, 68, 70, 71]. Supplementation with omega-3-fatty acids
may reduce serum triglycerides [72]. Given the risks of non-
alcoholic fatty-liver disease in CMS, alcohol consumption
should be low-to-moderate [34].
CMS associated hypertension may be treated by weight
loss alone. Other options imply a restriction of sodium to
about 4 g daily, or increases in the intake of potassium,
Table 1 Table of glycemic index (GI) and glycemic load (GL) in com-









Spaghetti, white boiled 44 ± 3 180 48 21
Spaghetti, full grain boiled 37 ± 5 180 42 16
Cornflakes 81 ± 3 60 52 42
Baguette 95 ± 15 60 30 30
Wheat bread 70 ± 0 60 28 20
Rye kernel bread 50 ± 4 60 24 12
Rice, long grain boiled 56 ± 2 150 41 23
Rice, brown boiled 55 ± 5 150 33 18
Potatoes baked 85 ± 12 150 30 26
Potatoes cooked 56 ± 101 150 17–26 11–
18
Potato chips 54 ± 3 90 63 33
Peas 35 ± 4 150 15 5
Carots (raw and
boiled)
47 ± 16 150 12 6
Kidneybeans (canned) 52 150 17 9
Lentils, green boiled 30 ± 4 150 17 5
Peanuts 14 ± 8 50 6 1
Bananas (raw) 52 ± 4 120 24 12
Grapes white (raw) 46 ± 3 120 18 8
Mango 51 ± 3 120 17 8
Watermelon 72 ± 13 120 6 4
Apples 38 ± 2 120 15 6
Oranges 42 ± 3 120 11 5
Peaches 42 ± 14 120 11 5
Strawberry (raw) 40 ± 7 120 3 1
Milk (full fat) 27 ± 4 250 12 3
Yoghurt (full fat) 36 ± 4 200 9 3
Ice cream 61 ± 7 50 13 8
Modified from [60]
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calcium, long-chain omega-3 fatty acids and protein, in par-
ticular vegetable protein [34]. TheOmni Heart Study (Optimal
Macronutrient Intake Trial for Heart Health) successfully
combined these factors subsequent to the DASH diet (dietary
approach to stop hypertension) promoting the intake of vege-
table, nuts, fruit, full grain, and lean milk products, poultry and
fish [73, 74]. This macronutrient modification is consistent
with the observed lowering of blood pressure via normalized
hyperinsulinemia by GI/GL restriction [30••, 50, 62] also in
the higher-fat DASH diet promoting full-fat dairy [75].
Of relevance, this nutritional modification with restricted
carbohydrate intake and more protein and fat intake—refer-
ring particularly to vegetable protein and vegetable oil—is
safe and lowers the risks for CAD and mortality [76].
Exercise Training in CMS
A recent meta-analysis confirmed that exercise has beneficial
effects on triglycerides, HDL, apolipoprotein A1, leptin, inter-
leukin-18, fibrinogen, and angiotensin II but not for C-reactive
protein, interleukin-6, tumor necrosis factor α, or adiponectin
[77]. The beneficial effects on insulin metabolism were sub-
stantially enlarged in the presence of CMS risk factors. Both
moderate and vigorous exercise training improved cardiomet-
abolic health [77].
Aerobic exercise is recommended for the sedentary be-
ginner as walking [78] or biking with incrementally in-
creasing duration and intensity along the measure of keep-
ing a conversation ongoing. Resistance training has also
shown beneficial effects on HbA1c, fat mass, and systolic
blood pressure but not on triglycerides, cholesterol levels,
and diastolic blood pressure in patients with dysglycemia
[79]. A measurable reduction of mortality was found even
for modest incremental increases of fitness and training
[80]. Further studies are needed to explore the apparent
superiority of aerobic training for risk factors in CMS and
the interaction with nutritionally deteriorated IR.
Bariatric Surgery
Bariatric surgery implies gastric banding, sleeve gastrectomy,
the Roux-en-Y gastric bypass, and biliopancreatic diversion
techniques. Recently, the indication was extended from severe
obesity to mild-to-moderate obesity combined with type-2
diabetes or CMS. Bariatric surgery may induce remission of
type-2 diabetes in about 60 % after 6 years and 36 % after
10 years [81]. The immediate effects of glucose lowering stem
from the sudden negative calorie balance and the increase of
GLP-1 response on food delivery into the small intestine.
Long-term effects are based on the excess weight loss with
its increase in insulin sensitivity. The prevalence of CMS may
be reduced by 60–95 % in 1–3 years [82] and that of hyper-
tension and the other risk factors by >30 % [22••].
Pharmacological Agents
From the three recent options for overweight treatment,
orlistat, sibutramine, and rimonabant, only orlistat is currently
available. It modestly lowers weight associated with improve-
ments in LDL, fasting insulin, blood pressure, and potentially
diastolic function [22••].
The pharmacological therapy of hypertension, of
dyslipoproteinemia, and of diabetes is well established. Its
discussion would be beyond the scope of this review that is
focused on new developments in association with CMS and
the risk of HF.
Non-Pharmacologic Therapeutic Strategies
for DD/HFPEF
Given the different cardiovascular comorbidities with their
specific treatments, therapeutic studies in DD/HFPEF need
specifically selected participants. The uncertainty about the
triggers for a progress from DD to HFPEFmakes the effective
treatment of DD an important preventive intervention so that
the discussion of DD and HFPEF treatment strategies is
combined.
By now, promising alternative strategies exist for treating
the underlying CMS. The respective clinical studies are rare
for several reasons. Firstly, HF, DD, and cardiovascular risks
are not routinely assessed in randomized trials on CMS.
Secondly, studies on life style changes most commonly do
not asses DD. Thirdly, research on nutrition and exercise is
difficult to finance being not in the promotional scientific pro-
gram of pharmaceutical industry whereas the beneficial poten-
tial for the affected patients may save millions of dollars an-
nually for the public health systems.
Dietary Approaches
In obese type-2 diabetics, weight loss nutrition (460 kcal daily
for 4 months) improved DD and myocardial triglyceride con-
tent [83]. In severe obesity, low GI diet vs. bariatric surgery
both induced relevant weight loss and improved LV mass and
DD after 1 year [84]. Moderate aerobic training was the exer-
cise intervention for a comparison of low-fat/high-carbohy-
drate nutrition (1800 kcal) with an isocaloric GL restricted
diet in obese type-2 diabetics (HbA1c 7,1 %) [30••] achieving
similar reductions in weight, total cholesterol, and HbA1c
after 3 weeks. Only GL restriction led to significant
improvements of postprandial glucose and insulin levels, IR,
triglycerides, blood pressure, diastolic function, and exercise
capacity, i.e. all factors of CMS. In the parallel group on
low-fat diet, these metabolic and functional parameters
remained unchanged but improved in the subsequent cross-
over design with GL restriction for 2 weeks [30••]. These
results were obtained in spite of a more than 50 % reduction
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of the antidiabetic medical therapy with GL restriction neces-
sary to avoid hypoglycemia vs. 16 % with low-fat nutrition.
This major reduction of antidiabetic medications implies that
modification/restriction of carbohydrate intake is a causal ther-
apy of CMS and its associated myocardial dysfunction [26•,
85]. Evidence confirms such a major reduction of antidiabetic
medication subsequent to GL restriction in type-2 and type-1
diabetes both for oral antidiabetics and for insulin [45••, 50, 85].
Regarding dietary effects on HFPEF in CMS, a case report
in an obese type-2 diabetic on insulin therapy with IR and a
recent onset of HFPEF showed reversal of DD by GL restric-
tion within 3 weeks but without relevant weight loss [66]. A
study in Bhypertensive^ HFPEF in 13 individuals with treated
hypertension and stable HFPEF demonstrated improvements
of blood pressure, DD, and HFPEF symptoms by the low-
sodium DASH diet [86] that implies also lowered GI/GL
[72]. Considering that the study participants had a mean
BMI of 35.5 ± 7.9 kg/m2 and that 43 % had type-2 diabetes,
the etiology of HFPEF might have been regarded to relate
both to IR and hypertensive heart disease but this issue was
not discussed in line with no information provided regarding
weight loss.
Summarizing, relevant weight loss or normalization of IR
induced by GL restriction or bariatric surgery unequivocally
improved DD [30••, 66, 83, 84, 86].
Exercise Training
In spite of the accepted beneficial effects of exercise for car-
diovascular risk factors in CMS, the effects on the associated
DD are ambiguous. Notably, the respective study designs for
exercise in obese type-2 diabetics have maintained the tradi-
tional low-fat/high-carbohydrate nutrition [87, 88]. Their am-
biguous outcome fits the results of the low-fat vs. GL restric-
tion dietary arm in spite of moderate aerobic training as
discussed above [30••]. A possible mechanism behind this
apparent discrepancy of exercise effects has recently been
shown: A single carbohydrate meal may worsen DD in type-
2 diabetics and non-diabetic individuals [89•]. This suggests
that the beneficial effects of exercise on DD may be neutral-
ized by nutritional deterioration in IR.
Improved physical performance and DD by exercise train-
ing have been shown in HFPEF patients with overweight
(BMI 31 ± 5 kg/m2) and additional ≥1 risk factors [31] but
this report, like so many exercise studies, does not report the
nutritional recommendations during the intervention.
A recent meta-analysis of six studies concluded that exer-
cise in HFPEF does not improve DD in spite of improvements
in cardiorespiratory fitness and quality of life [90]. However,
the echocardiographic parameters used to assess DD relied on
E/A and/or deceleration time that imply bimodal changes in
the course of diastolic disease rendering the respective inter-
pretation of interventional results difficult.
Summarizing these exercise studies, the assessment of di-
astolic function should use tissue Doppler derived and quan-
tifiable methods of assessing DD [21••]. This diagnostic meth-
od should be applied for assessing the potential of IR normal-
ization for the treatment/reversal of DD via both specific ex-
ercise and nutritional interventions.
Pharmaceutical Therapy
Given the diverse comorbidities of DD/HFPEF, the respective
treatment approach needs to primarily address this underlying
problem. Concerning CAD, arterial hypertension, and periph-
eral vascular disease, the respective treatments are well
established and beyond the scope of this review. Instead, dis-
cussion presents developments in the therapy of IR and type-2
diabetes with potential for improving DD/HF.
Insulin Resistance
The biguanide metformin improves hepatic and peripheral IR
and LV diastolic function in patients with type-2 diabetes [91].
It affects translocation of glucose transporters Glut1 and
Glut4, prevents hyperglycemia induced abnormalities in re-
laxation by reducing intracellular Ca transients, and maintains
metabolic flexibility [22••].
Glitazones had been designed to increase insulin sensitivi-
ty. However, the associated effect on renal collecting ducts is
fluid retention so that use of these drugs was not recommend-
ed for patients with (advanced) HF. In type-2 diabetics without
cardiac disease, DD was improved by pioglitazone [92].
Within the GPL-1 analogues, liraglutide in the LEADER
trial [93] has just been announced to effectively improve CV
deaths but not systolic HF whereas lixisenatide did not alter
cardiovascular events and HF hospitalization in patients with
type-2 diabetes and acute coronary syndrome [94]. Studies on
DD/HF in diabetes are underway.
Data for the protective action of DDP-4 inhibitors are in-
conclusive. Sitagliptin was shown to potentially improve DD
[95]. In a large retrospective study, the use of DPP-4 inhibitors
compared with sulphonylureas was associated with a reduced
risk of hospitalization for HFwhereas an earlier comparison of
saxagliptin with placebo had demonstrated an increased risk
for HF hospitalization [96].
The recent sodium/glucose cotransporter-2 (SGLT2)
inhibitor empagliflozin lowers blood glucose irrespective
of beta-cell function and IR by blocking glucose reab-
sorption in the proximal renal tubulus with subsequent
excretion of abundant glucose. This elimination pre-
cludes protective metabolic mechanisms against hyper-
glycemic and insulinemic peaks. The EMPA-REG out-
come study data showed a decrease of CV deaths and
an improved hospitalization rate with HF [97•]. Studies
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on DD and HF in patients without and with type-2 dia-
betes are underway.
Glucose-Lowering Antidiabetic Therapy
Awareness has grown for the risks from hypoglycemic events
and/or the simultaneous use of several antidiabetics [64].
Nevertheless, evidence shows that glucose control does matter
in patients with diabetes [98], especially for the risk of DD/HF
from postprandial dysmetabolism and IR [27, 99•]. Besides
metformin, insulin therapy may be protective: multiple daily
injection (MDI) vs. mixed insulin regimen and the use of
analogue MDI vs. human insulin MDI regimen have shown
specifically lowered postprandial glucose levels and improved
myocardial function and perfusion [8, 99•, 100].
Unfortunately, the assessment of postprandial metabo-
lism is ignored in most evidence creating studies.
Furthermore, the different stages of IR deserve consider-
ation for tailoring therapeutic strategies. Given the nutri-
tional induction of postprandial hyperglycemia in IR and
type-2 diabetes, carbohydrate restriction remains the
most appropriate antidiabetic therapy.
Summarizing, patients with significant hyperglycemia
benefit most from immediate insulin-based strategies that
improve especially postprandial glucose, and those pa-
tients with stable glucose control should receive immedi-
ate carbohydrate restriction combined with meticulous
adaptation of their individual antidiabetic regimen.
Conclusion: Risk of DD/HFPEF in CMS
The diagnostic design of respective therapeutical studies
in overt HFPEF or for its prevention is substantially and
biomathematically improved by the new approach for
quantification of DD via the age dependence of diastolic
function [21••] and should apply a homogenous selection
of CMS individuals in order to create the necessary sta-
tistical evidence.
Patients with CMS and DD have as underlying key mech-
anism depleted cardiac energetic reserve caused by IR. Given
unequivocous clinical studies on the dietary treatment of DD/
HFPEF and the consistent evidence from dietary treatment of
the underlying CMS, causal therapy is a normalization of in-
sulin sensitivity by the therapeutic use of diets with modified
macronutrient composition: increased vegetables, fruits and
salads, reduced GL in favor of full grain products, and liber-
alization of fat in favor of MUFA/PUFA associated with an
aerobic exercise program.
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